Therakind Limited

← The SEC Ephemeris: the whole map

Therakind Limited Jylamvo

In the graph: all 1 documents (3 pages).

Application: NDA 212479
Ticker: Therakind Limited
Product: Jylamvo
Disease area: Not yet classified
Response path: Not yet classified
Complete Response Letters: December 22, 2021

From FDA letters and SEC filings. Not investment or medical advice.

Not yet classified

Shilpa Medicare Limited bortezomib
Spectrum Pharmaceuticals, Inc. SPI-2012
Spes Pharmaceuticals Inc. fosaprepitant
SQ Innovation, Inc. furosemide
Stealth BioTherapeutics Inc. elamipretide
StemCyte, Inc. Hematopoietic Progenitor Cells
Sun Pharma Advanced Research Company Limited Elepsia XR
Sun Pharma Global FZE Levetiracetam
Sun Pharmaceutical Industries Limited nilotinib
Sunovion Pharmaceuticals Inc. Kynmobi
Supernus Pharmaceuticals, Inc. viloxazine hydrochloride
Swedish Orphan Biovitrum AB (publ) sirolimus
SYDNEXIS Inc. atropine sulfate
Takeda Pharmaceuticals U.S.A., Inc. Eohilia
Tanvex BioPharma USA, Inc. TX05
Telix Pharmaceuticals (US) Inc. this action
Teva Neuroscience, Inc. risperidone
Teva Pharmaceuticals, Inc. TVB-009
Teva Pharmaceuticals USA Fulvestrant
Teva Women’s Health, Inc. progesterone
Therakind Limited Jylamvo
TherapeuticsMD, Inc. estradiol
Thomas Chaly, Ph.D., FAIC Fluorodopa F
Trevena, Inc. Oliceridine
Tris Pharma, Inc. oxybate
UGB, Inc. UCB4940
Ultragenyx Pharmaceutical Inc. rebisufligene etisparvovec
Unicycive Therapeutics Inc. oxylanthanum carbonate
United Therapeutics Corporation treprostinil
University of California San Francisco Floretyrosine F
Valeant Pharmaceuticals Ireland tetracaine hydrochloride
Venatorx Pharmaceuticals, Inc.
Verrica Pharmaceuticals Inc. cantharidin
ViiV Healthcare Company CABENUVA®
Vyluma, Inc. atropine sulphate
Xbrane Biopharma AB We have completed our review of this application
Xellia Pharmaceuticals, ApS Vancomycin
Xeris Pharmaceuticals, Inc. Gvoke
Xspray Pharma AB nilotinib

All 283 on the full map →

Group by

Build queue · replay at pipeline speed